Observational Diagnoses of Extratropical Ozone STE from 2005-2010

The transport of ozone from the stratosphere to the extratropical troposphere is an important boundary condition to tropospheric chemistry. However, previous direct estimates from models and indirect estimates from observations have poorly constrained the magnitude of ozone stratosphere-troposphere exchange (STE). In this study we provide a direct diagnosis of the extratropical ozone STE using data from the Microwave Limb Sounder on Aura and output of the MERRA reanalysis over the time period from 2005 to the present. We find that the mean annual STE is about 275 Tg yr-1 and 205 Tg yr-1 in the NH and SH, respectively. The interannual variability of the magnitude is about twice as great in the NH than the SH. This variability is dominated by the seasonal variability during the late winter and spring. A comparison of the ozone flux to the mass flux reveals that there is not a simple relationship between the two quantities. This presentation will also examine the magnitude and distribution of ozone in the lower stratosphere relative to the years of maximum and minimum ozone ST

Recovery of temperature records from slow-growing corals by fine scale sampling of skeletons

Author Posting. © American Geophysical Union, 2007. This article is posted here by permission of American Geophysical Union for personal use, not for redistribution. The definitive version was published in Geophysical Research Letters 34 (2007): L17706, doi:10.1029/2007GL030967.We used laser ablation inductively coupled plasma mass spectrometry (LA ICP-MS) to analyze Sr/Ca ratios in 5 colonies of the Atlantic corals, Diploria labyrinthiformis and Montastrea franski, each growing less than 5 mm yr−1. By targeting the centers of septa we avoided thickening deposits to achieve an analytical sampling resolution of 5-10 days. The sensitivity of Sr/Ca to temperature (−0.096 mmol/mol/°C) is ∼3 times higher than previously reported for these species and equivalent to that exhibited by fast-growing Porites corals from the Indo-Pacific. The Sr/Ca-sea surface temperature (SST) calibrations derived from these corals were not statistically different and were independent of colony growth rate over the period studied. Data from 4 D. labyrinthiformis colonies were pooled to produce a single Sr/Ca-SST calibration with a calculated standard error on the predicted ocean temperature of ±0.51°C. Applying our calibration to Sr/Ca analyses of D. labyrinthiformis skeleton deposited in the late 18th century indicated that average annual sea surface temperatures around Bermuda were ∼1°C cooler than today.This study was supported by a WHOI Ocean Life Institute fellowship to ALC, by OLI grant 25051316 to ALC and SRT, by NSF OCE-0402728 and NSF OCE- 0215905

Defining the gap between research and practice in public relations programme evaluation - towards a new research agenda

The current situation in public relations programme evaluation is neatly summarized by McCoy who commented that 'probably the most common buzzwords in public relations in the last ten years have been evaluation and accountability' (McCoy 2005, 3). This paper examines the academic and practitioner-based literature and research on programme evaluation and it detects different priorities and approaches that may partly explain why the debate on acceptable and agreed evaluation methods continues. It analyses those differences and proposes a research agenda to bridge the gap and move the debate forward

Peginesatide in patients with anemia undergoing hemodialysis

BACKGROUND: Peginesatide, a synthetic peptide-based erythropoiesis- stimulating agent (ESA), is a potential therapy for anemia in patients with advanced chronic kidney disease. METHODS: We conducted two randomized, controlled, open-label studies (EMERALD 1 and EMERALD 2) involving patients undergoing hemodialysis. Cardiovascular safety was evaluated by analysis of an adjudicated composite safety end point - death from any cause, stroke, myocardial infarction, or serious adverse events of congestive heart failure, unstable angina, or arrhythmia - with the use of pooled data from the two EMERALD studies and two studies involving patients not undergoing dialysis. In the EMERALD studies, 1608 patients received peginesatide once monthly or continued to receive epoetin one to three times a week, with the doses adjusted as necessary to maintain a hemoglobin level between 10.0 and 12.0 g per deciliter for 52 weeks or more. The primary efficacy end point was the mean change from the baseline hemoglobin level to the mean level during the evaluation period; noninferiority was established if the lower limit of the two-sided 95% confidence interval was -1.0 g per deciliter or higher in the comparison of peginesatide with epoetin. The aim of evaluating the composite safety end point in the pooled cohort was to exclude a hazard ratio with peginesatide relative to the comparator ESA of more than 1.3. RESULTS: In an analysis involving 693 patients from EMERALD 1 and 725 from EMERALD 2, peginesatide was noninferior to epoetin in maintaining hemoglobin levels (mean between-group difference, -0.15 g per deciliter; 95% confidence interval [CI], -0.30 to -0.01 in EMERALD 1; and 0.10 g per deciliter; 95% CI, -0.05 to 0.26 in EMERALD 2). The hazard ratio for the composite safety end point was 1.06 (95% CI, 0.89 to 1.26) with peginesatide relative to the comparator ESA in the four pooled studies (2591 patients) and 0.95 (95% CI, 0.77 to 1.17) in the EMERALD studies. The proportions of patients with adverse and serious adverse events were similar in the treatment groups in the EMERALD studies. The cardiovascular safety of peginesatide was similar to that of the comparator ESA in the pooled cohort. CONCLUSIONS: Peginesatide, administered monthly, was as effective as epoetin, administered one to three times per week, in maintaining hemoglobin levels in patients undergoing hemodialysisSupported by Affymax and Takeda Pharmaceutica

DNM1 encephalopathy: A new disease of vesicle fission.

ObjectiveTo evaluate the phenotypic spectrum caused by mutations in dynamin 1 (DNM1), encoding the presynaptic protein DNM1, and to investigate possible genotype-phenotype correlations and predicted functional consequences based on structural modeling.MethodsWe reviewed phenotypic data of 21 patients (7 previously published) with DNM1 mutations. We compared mutation data to known functional data and undertook biomolecular modeling to assess the effect of the mutations on protein function.ResultsWe identified 19 patients with de novo mutations in DNM1 and a sibling pair who had an inherited mutation from a mosaic parent. Seven patients (33.3%) carried the recurrent p.Arg237Trp mutation. A common phenotype emerged that included severe to profound intellectual disability and muscular hypotonia in all patients and an epilepsy characterized by infantile spasms in 16 of 21 patients, frequently evolving into Lennox-Gastaut syndrome. Two patients had profound global developmental delay without seizures. In addition, we describe a single patient with normal development before the onset of a catastrophic epilepsy, consistent with febrile infection-related epilepsy syndrome at 4 years. All mutations cluster within the GTPase or middle domains, and structural modeling and existing functional data suggest a dominant-negative effect on DMN1 function.ConclusionsThe phenotypic spectrum of DNM1-related encephalopathy is relatively homogeneous, in contrast to many other genetic epilepsies. Up to one-third of patients carry the recurrent p.Arg237Trp variant, which is now one of the most common recurrent variants in epileptic encephalopathies identified to date. Given the predicted dominant-negative mechanism of this mutation, this variant presents a prime target for therapeutic intervention